Compare FROG & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FROG | HAE |
|---|---|---|
| Founded | 2008 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 3.7B |
| IPO Year | 2020 | 1991 |
| Metric | FROG | HAE |
|---|---|---|
| Price | $69.30 | $83.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 9 |
| Target Price | $62.39 | ★ $83.67 |
| AVG Volume (30 Days) | ★ 1.9M | 831.1K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.54 |
| EPS | N/A | ★ 3.44 |
| Revenue | $502,612,000.00 | ★ $1,327,850,000.00 |
| Revenue This Year | $24.89 | N/A |
| Revenue Next Year | $16.63 | $6.01 |
| P/E Ratio | ★ N/A | $24.31 |
| Revenue Growth | ★ 22.69 | N/A |
| 52 Week Low | $27.00 | $47.32 |
| 52 Week High | $70.43 | $87.32 |
| Indicator | FROG | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 70.71 | 70.71 |
| Support Level | $59.27 | $82.30 |
| Resistance Level | $70.43 | $87.32 |
| Average True Range (ATR) | 2.61 | 2.20 |
| MACD | 0.42 | -0.56 |
| Stochastic Oscillator | 85.84 | 61.70 |
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from Israel and also has its presence in United States, India and other regions.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.